Skip to main content
107 search results for:

MET inhibitors 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 18-10-2022 | PI3K inhibitors | News | Article

    Meta-analysis reveals high risk for cutaneous AEs with PI3K inhibitors

    The use of PI3K inhibitors for the treatment of cancer is associated with a high risk for developing cutaneous adverse events, suggests a meta-analysis published in JAMA Oncology .

  2. 01-08-2022 | Non-small-cell lung cancer | Adis Journal Club | Article
    Targeted Oncology

    Randomized Versus Real-World Evidence on the Efficacy and Toxicity of Checkpoint Inhibitors in Cancer in Patients with Advanced Non-small Cell Lung Cancer or Melanoma: A Meta-analysis

    Authors: Evangelos Digkas, Anthony Jagri Tabiim, Daniel Smith & Antonis Valachis Abstract Background Both randomized controlled trials (RCTs) and real-world evidence (RWE) studies provide results regarding the efficacy and toxicity of checkpoint inhibitors in cancer patients.

  3. 05-07-2021 | Adis Journal Club | Article
    Targeted Oncology

    Risk of Infection with Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis

    DOI [Teaser] Key Points The use of immune checkpoint inhibitors (ICIs) in monotherapy is associated with a lower risk of all-grade infections.

  4. 14-05-2019 | Quality of life | Article

    An immunotherapy survivor population: health-related quality of life and toxicity in patients with metastatic melanoma treated with immune checkpoint inhibitors

    O’Reilly A et al. Support Care Cancer 2020; 28: 561. doi:10.1007/s00520-019-04818-w

  5. 26-07-2017 | Teaser

    Improving cancer immunotherapy with DNA methyltransferase inhibitors

    Solid tumors are often not responsive to immunotherapy but recent findings suggest that epigenetic modifying drugs can prime antitumor immunity. This review describes how DNA methyltransferase inhibitors may aid the establishment of antitumor immunity. Summary points Two DNA methyltransferases inhibitors (DNMTi) are currently approved by the US Food and Drug Administration: azacitidine and decitabine. DNMTi have been shown to increase tumor immunogenicity by upregulating the production of the class I major histocompatibility complex (MHC I) whilst also increasing the levels of antigens displayed in MHC I, in particular cancer-testis antigens. Furthermore, DNMTi have been demonstrated to stimulate natural killer cell- and CD8 T cell-mediated cytotoxicity by inducing the expression of chemokines and activating associated ligands on the surface of tumors cells. DNMTi can also decrease natural and tumor-induced immunosuppression by regulatory adaptive and innate immune cells. The ability of DNMTi to widely prime the immune system makes them a great candidate for combinations with other immunotherapies, particularly immune checkpoint blockade. Multiple phase 1 clinical trials employing DNMTi in combination with a variety of immune-based therapies are currently ongoing. Saleh MH, Wang L, & Goldberg MS. Cancer Immunol Immunother 2016; 65: 787–796. doi:10.1007/s00262-015-1776-3

  6. 04-07-2023 | Non-small-cell lung cancer | News | Article

    Adagrasib shows intracranial efficacy in KRYSTAL-1 trial

    Negrao et al report that the majority of CNS-specific TRAEs, such as dysgeusia, ataxia, aphasia, headache, and insomnia, were of grade 1–2, with just four patients experiencing grade 3 events – three cases of dizziness and one of encephalopathy – and no events of grade 4 or 5. medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2023 Springer Healthcare Ltd, part of the Springer Nature Group J Clin Oncol 2023; doi:10.1200/JCO.23.00046

  7. 27-07-2018 | Advanced breast cancer | Article

    CDK4/6 inhibitors in advanced hormone receptor-positive/HER2-negative breast cancer: a systematic review and meta-analysis of randomized trials

    Messina C et al. Breast Cancer Res Treat 2018; 172: 9. doi:10.1007/s10549-018-4901-0

  8. 05-06-2023 | Breast cancer | Conference coverage | Article
    ASCO 2023

    Adjuvant ribociclib reduces recurrence risk in early breast cancer

    He added that these findings “support ribociclib and nonsteroidal aromatase inhibitors as a new treatment of choice in a broad population – broader than we’ve seen before – of patients with stage II and stage III disease.”

  9. 08-12-2015 | Treatment | Article

    Improving cancer immunotherapy with DNA methyltransferase inhibitors

    Solid tumors are often not responsive to immunotherapy but recent findings suggest that epigenetic modifying drugs can prime antitumor immunity. This review describes how DNA methyltransferase inhibitors may aid the establishment of antitumor immunity. Saleh MH, Wang L, & Goldberg MS. Cancer Immunol Immunother 2016; 65: 787–796. doi:10.1007/s00262-015-1776-3

  10. 20-04-2023 | Urothelial cancer | At a glance | Article

    At a glance: Second and later line immunotherapy for advanced urothelial carcinoma

    A summary of the key trial publications on the use of PD-1 pathway and CTLA-4 inhibitors alone or in combination in the second-line or later treatment of locally advanced and metastatic urothelial carcinoma. This independent article was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany

  11. 16-11-2022 | Non-small-cell lung cancer | News | Article

    Telisotuzumab vedotin plus erlotinib may offer novel advanced NSCLC approach

    Phase 1b trial findings indicate that telisotuzumab vedotin, given in combination with erlotinib, may have potential as a treatment option for progressing EGFR mutation-positive non-small-cell lung cancer with c-Met overexpression.

  12. 12-10-2022 | Small-cell lung cancer | News | Article

    First-line serplulimab plus chemo improves extensive-stage SCLC survival

    The authors of a related editorial say that “[h]ad there not been 2 prior RCTs [randomized controlled trials], demonstrating benefit with 2 other immune checkpoint inhibitors, this trial would have been practice changing.”

  13. 30-08-2022 | Immunotherapy | News | Article

    ICIs favorably associated with patient-reported QoL

    A meta-analysis has revealed a favorable association between immune checkpoint inhibitors as monotherapy and patient-reported outcomes and quality of life.

  14. 06-08-2021 | Urothelial cancer | Feature | Article
    Updated January 2023

    At a glance: First-line immunotherapy for advanced urothelial carcinoma

    In this article, we provide an overview of the published trials of PD-1 pathway and CTLA-4 inhibitors – used as monotherapy, in combination with chemotherapy, or as maintenance – in the first-line treatment of locally advanced or metastatic urothelial cancer.

  15. 11-08-2022 | WCLC 2022 | Conference coverage | Article

    KEYNOTE-604 update bolsters first-line pembrolizumab–chemo for extensive-stage SCLC

    The hazard ratio (HR) for OS also favored the addition of pembrolizumab in this analysis, but “the prespecified significance threshold was not met,” said Rudin.

  16. 13-07-2022 | Immunotherapy | News | Article

    ICI therapy feasible in advanced cancer patients with kidney transplant using immunosuppression

    None of the 17 individuals met the primary endpoint of irretrievable allograft loss without tumor response, the team reports.

  17. 07-06-2022 | ASCO 2022 | Conference coverage | Article

    OS data reported from TheraP trial of LuPSMA in mCRPC

    Hofman also presented the OS data for the 61 so-called “screen-fail” patients who met all the inclusion and exclusion criteria but were excluded from the trial as a result of low PSMA levels or FDG discordance.

  18. 05-06-2022 | ASCO 2022 | Conference coverage | Article

    Survival benefits unclear for add-on palbociclib in advanced breast cancer

    After a median 90 months of follow-up, the required number of OS events were met (405 deaths in total) and Finn reported the findings at the meeting.

  19. 11-04-2022 | ALK-mutated NSCLC | Interview | Article

    Pathologic testing for ALK and ROS1 aberrations in NSCLC

    So one mechanism will be on-target, so it will be through mutations in ALK genes or ROS1 gene, or It can be off-target, meaning that it will be an activation of other pathway like MET, for instance, MET amplification.

  20. 20-11-2018 | Advanced breast cancer | Article

    Selecting the optimal position of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer – the SONIA study: study protocol for a randomized controlled trial

    van Ommen-Nijhof A et al.  BMC Cancer 2018; 18:1146. doi:10.1186/s12885-018-4978-1

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.